Lucid Diagnostics Inc (LUCD)

Currency in USD
0.9911
-0.0289(-2.83%)
Closed·
1.0300+0.0389(+3.92%)
·
LUCD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.95011.0298
52 wk Range
0.94951.7000
Key Statistics
Prev. Close
1.02
Open
1.01
Day's Range
0.9501-1.0298
52 wk Range
0.9495-1.7
Volume
1.38M
Average Volume (3m)
782.33K
1-Year Change
-21.3413%
Book Value / Share
-0.04
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LUCD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.1000
Upside
+313.68%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Lucid Diagnostics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 4.1000
(+313.68% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Maxim Group
Buy2.00+101.80%3.00MaintainMay 15, 2026
BTIG
Buy2.50+152.24%-MaintainMar 30, 2026
Needham
Buy3.00+202.69%-MaintainMar 26, 2026
Canaccord
Buy3.00+202.69%-MaintainMar 26, 2026
Ascendiant Capital
Buy8.25+732.41%8.00MaintainDec 10, 2025

Lucid Diagnostics Inc SWOT Analysis


Market Disruption
Lucid Diagnostics aims to revolutionize BE-EAC screening with EsoGuard/EsoCheck technology, targeting a $25 billion U.S. market opportunity
Financial Crossroads
Despite 179% YoY revenue growth, LUCD faces challenges with cash burn and revised 2025 revenue projections, reflecting market uncertainties
Reimbursement Hurdles
Progress in clinical validation studies bolsters reimbursement efforts, but pricing pressures could impact future revenue and market adoption
Strategic Outlook
Analysts set price targets between $2.00 and $3.00, as LUCD navigates growth challenges and explores potential market expansion opportunities
Read full SWOT analysis

Lucid Diagnostics Inc Earnings Call Summary for Q1/2026

  • Q1 2026 EPS of -$0.07 matched estimates, but revenue of $1.26M missed forecasts by 8.7% due to conservative recognition policy amid reimbursement uncertainty.
  • Performed 3,177 EsoGuard tests exceeding targets; recognizes only 14% of billable value due to transitional reimbursement environment and collection constraints.
  • Cash position stands at $44.8M post-April financing after raising $16.8M through public offering; high burn rate remains a concern for investors.
  • Strategic focus on Medicare and VA opportunities expected to drive growth; analysts forecast 109% revenue growth for FY2026 with price targets of $2.50-$9.00.
  • Stock rose 0.98% to $1.03 in premarket trading despite revenue miss; trading near 52-week low of $0.95 with market cap of $192M.
Last Updated: 2026-05-14, 09:44 a/m
Read Full Transcript

Earnings

Latest Release
May 14, 2026
EPS / Forecast
-0.07 / -0.07
Revenue / Forecast
1.26M / 1.38M
EPS Revisions
Last 90 days

LUCD Income Statement

Compare LUCD to Peers and Sector

Metrics to compare
LUCD
Peers
Sector
Relationship
P/E Ratio
−3.2x−0.2x−0.5x
PEG Ratio
−0.09−0.020.00
Price/Book
−30.8x1.3x2.6x
Price / LTM Sales
36.8x1.9x3.2x
Upside (Analyst Target)
176.5%437.3%52.3%
Fair Value Upside
Unlock43.9%8.8%Unlock

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company’s flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
15.08M7.99%15.39M
Other Institutional Investors
58.63M31.07%59.80M
Public Companies & Retail Investors
114.96M60.93%117.26M
Total
188.67M100.00%192.44M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
PAVmed Inc.20.57%38,816,90338,471
The Vanguard Group, Inc.2.63%4,968,6084,924

People Also Watch

33.69
PKE
-2.04%
23.320
LYTS
-3.44%
176.04
LSTR
+4.82%
6.46
CV
-11.51%
105.33
LNN
-1.07%

FAQ

What Is the Lucid Diagnostics (LUCD) Stock Price Today?

The Lucid Diagnostics stock price today is 0.9911 USD.

What Stock Exchange Does Lucid Diagnostics Trade On?

Lucid Diagnostics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Lucid Diagnostics?

The stock symbol for Lucid Diagnostics is "LUCD."

What Is the Lucid Diagnostics Market Cap?

As of today, Lucid Diagnostics market cap is 194.5900M USD.

What Is Lucid Diagnostics's Earnings Per Share (TTM)?

The Lucid Diagnostics EPS (TTM) is -0.4857.

When Is the Next Lucid Diagnostics Earnings Date?

Lucid Diagnostics will release its next earnings report on Aug 17, 2026.

From a Technical Analysis Perspective, Is LUCD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Lucid Diagnostics Stock Split?

Lucid Diagnostics has split 0 times.

How Many Employees Does Lucid Diagnostics Have?

Lucid Diagnostics has 82 employees.

What is the current trading status of Lucid Diagnostics (LUCD)?

As of May 16, 2026, Lucid Diagnostics (LUCD) is trading at a price of 0.9911 USD, with a previous close of 1.0200 USD. The stock has fluctuated within a day range of 0.9501 USD to 1.0298 USD, while its 52-week range spans from 0.9495 USD to 1.7000 USD.

What Is Lucid Diagnostics (LUCD) Price Target According to Analysts?

The average 12-month price target for Lucid Diagnostics is 4.1000 USD, with a high estimate of 9 USD and a low estimate of 2.5 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +313.68% Upside potential.

What Is the LUCD Premarket Price?

LUCD's last pre-market stock price is 1.0100 USD. The pre-market share volume is 16,020.0000, and the stock has decreased by -0.0100, or -0.9800%.

What Is the LUCD After Hours Price?

LUCD's last after hours stock price is 1.0300 USD, the stock has decreased by 0.0389, or 3.9200%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.